Container Closure Systems for Human Drugs and Biological Products; Draft Guidance for Industry; Availability
The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry entitled "Container Closure Systems for Human Drugs and Biological Products." This document provides guiding principles for evaluating the quality of container closure systems (CCSs) used to package drugs and biological products, for human use. This includes CCSs that are also device constituent parts of combination products and CCSs used to package the drug or biological product constituent parts of combination products.
Read the official notice →Source: Federal Register (FDA/USDA food labeling) · US Government work (public domain). This is a short, attributed summary; the full authoritative text lives on the authority’s own site. LabelYog does not author or endorse it — confirm compliance against the destination market’s official source.
More from United States
- 2026 Unified Agenda of Regulatory and Deregulatory Actions regulatory
- Introduction to the Unified Agenda of Federal Regulatory and Deregulatory Actions-2026 regulatory
- Regulatory Agenda regulatory
- Calcium Carbonate; Exemption From the Requirement of a Pesticide Tolerance regulatory
- Type VII Veterinary Master File for Research and Development and Risk Reviews; Guidance for Industry; Availability regulatory
- Determining Whether To Submit an ANDA or a 505(b)(2) Application; Draft Guidance for Industry; Availability regulatory
What this means for your label
A notice like this changes what a pack must carry. These are the rules we build against, starting with US FDA.